Fisher Asset Management LLC Buys 69,223 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Fisher Asset Management LLC increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 14.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 547,331 shares of the company's stock after acquiring an additional 69,223 shares during the period. Fisher Asset Management LLC owned about 0.38% of Denali Therapeutics worth $15,944,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Denali Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company's stock worth $225,069,000 after purchasing an additional 133,810 shares in the last quarter. Marshall Wace LLP raised its position in Denali Therapeutics by 12.7% during the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock worth $56,165,000 after acquiring an additional 272,454 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Denali Therapeutics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock valued at $32,913,000 after acquiring an additional 84,522 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after acquiring an additional 149,939 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Denali Therapeutics in the 2nd quarter valued at about $24,454,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. This trade represents a 14.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 86,578 shares of company stock worth $2,474,440. 7.90% of the stock is currently owned by insiders.

Denali Therapeutics Stock Up 1.9 %

Shares of DNLI stock traded up $0.48 on Thursday, reaching $25.16. The company had a trading volume of 577,772 shares, compared to its average volume of 1,071,990. The business's 50-day moving average is $27.53 and its 200 day moving average is $24.43. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The stock has a market capitalization of $3.62 billion, a PE ratio of -9.12 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the company earned ($0.72) EPS. On average, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Citigroup lifted their price target on Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Bank of America increased their price target on Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $38.90.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.